Screenshot of bionews.com 340B drug discount program story
The 340B program “is buckling under its own weight and overdue for reform,” BIO says in its blog.

340B “Overdue for Reform,” Industry Trade Group BIO Says in Blog

The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.

BIO, which is marking its 30th anniversary in 2023, has experienced inner turmoil in recent years including the departure of its CEO Dr. Michelle McMurry-Heath after a short tenure. Pharmaceutical Research and Manufacturers of America mostly overshadows it on 340B matters.

The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer